Return to List

Study Summary
No. 2007-0436:.......Lymphoma; Solid Tumors......Aung Naing......Investigational Cancer Therapeutics
.
Study Summary Title
Study Summary
Number:
2007-0436
Study Title:A COMBINED RISING SINGLE-DOSE (RSD) AND RISING MULTIPLE-DOSE (RMD) PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF KX2-391 IN PATIENTS WITH ADVANCED MALIGNANCIES THAT ARE REFRACTORY TO CONVENTIONAL THERAPIES
.
Physician New Patient Referral
Name:Aung NaingPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Investigational Cancer TherapeuticsReferring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-563-1930
Contact us about clinical trials
.
General Information
Disease Group:Lymphoma
Solid Tumors
Supported By:Kinex Pharmaceuticals
Phase of Study:Phase IReturn
Visit:
This study includes a maximum of 19 scheduled visits over 14 weeks per patient
starting from Screening through the completion of RSD and the first 2 cycles of
RMD dosing.
Treatment
Agents:
KX2-391Home Care:N/A
Treatment Loc:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated
Length of Stay
in Houston:
N/A
Description/
Intervention:
The goal of this clinical research study is to find the highest tolerable dose
of KX2-391 that can be given to patients with advanced cancer. The safety of
this drug will also be studied. This is the first time KX2-391 has ever been
given to humans.
.
Study Objectives / Outcomes
Primary Objective
  • To define the maximum tolerated dose (MTD) of KX2-391 when administered as multiple oral solutions to patients with advanced malignancies when administered on a 3-week on 1-week off dosing schedule.
  • To define the MTD of KX2-391 when administered continuously as multiple oral solutions to patients with advanced malignancies

Secondary Objectives
  • To determine the safety and tolerability of KX2-391 oral solution when given as single and multiple oral doses to patients with advanced malignancies
  • To characterize the pharmacokinetic profile of single dosing and multiple dosing of KX2-391 in patients with advanced malignancies
  • To determine the biological effects of KX2-391
  • To evaluate antitumor activity (tumor response) of KX2-391
  • To evaluate the effect of food on the PK of KX2-391
.
Study Status Information
Study Activation / Registration Date:11/19/2007
IRB Review and Approval Date:11/19/2007
Study Type:Phase I
Recruitment Status:Terminated
Projected Accrual:50
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:1) Signed written informed consent

2) Adults over age 18 years of age

3) Confirmed advanced solid tumor or lymphoma that may be metastatic or unresectable and for which standard curative or palliative measure do not exist or are no longer effective; patients with treated brain cancer (stable disease for at least 30 days prior to Day 1 of dosing) or ocular metastases are also eligible

4) ECOG performance status of 0-2

5) Life expectancy of at least 14 weeks

6) Adequate bone marrow reserve as demonstrated by absolute neutrophil count (ANC) >/= 1.5 x 10^9/L, platelet count (PLT) >/= 100 x 10^9/L or hemoglobin (Hgb) >/= 10 g/L

7) Adequate liver function as demonstrated by serum bilirubin, alanine aminotransferase (ALT), and aspartate transaminase (AST) </= 2.5 x upper limit of normal (ULN). Of note, if the patient has known Gilbert's disease the bilirubin must be below 5 x ULN.

8) Adequate renal function [serum creatinine </= 1.5 x ULN or calculated creatinine clearance (using Cockcroft and Gault method) > 60 ml/min]

9) Negative pregnancy test for females at Screening, preferably done within 1 week before Day 1 of dosing (not applicable to patients with bilateral oophorectomy and/or hysterectomy or are post menopausal for at least 12 months)

10) Willing to abstain from sexual activity or practice physical barrier contraception 28 days before Day 1 of dosing and 6 months after the last dose for the patient

11) Signed written informed consent for tumor biopsy for the additional 10 subjects that will be dosed at the MTD and who have accessible tumors

12) For the additional 10 patients in the expansion phase, the patients must have evidence of progressive disease by RECIST within 3 months (90 days) of the time they are enrolled in the study. However, other evidence of disease progression, including symptoms, serology, evidence of increasing ascites, etc, can be evaluated on a case by case basis.

Exclusion Criteria:1) Have not recovered to Grade (0 or 1) toxicity from previous anti-cancer treatments or previous investigational agents

2) Received investigational agents within 28 days of first day of study

3) Received extensive radiation therapy including sternum, pelvis, scapulae, vertebrae or skull, </= 4 weeks or recieved low dose palliative radiation therapy limited to limbs </= 1 week prior to starting study drug, or who have not recovered from side effects of such therapy

4) Currently taking or having received hormones (e.g. estrogen or progesterone) within 7 days prior to the first dose of drug. Note: LHRH analogs are permissible

5) Using moderate or strong CYP450 34A modulators (inducers or inhibitors) within 2 weeks or 5 half-lives (whichever is shorter) prior to Day 1 of dosing and during the study

6) Pregnant or breast-feeding

7) Major surgery within 4 weeks prior to Day 1 of dosing

8) Major surgery to the upper gastrointestinal tract, or have a history of inflammatory bowel disease, malabsorption syndrome or other medical condition that may interfere with oral drug absorption

9) Signs or symptoms of other major diseases including, but not limited to: end organ failure, major chronic illnesses other than cancer, coagulation disorders, hemolytic conditions (e.g. sickle cell disease ) or active infections which, in the opinion of the investigator, makes it undesirable for the subject to participate in the study

10) History of major cardiac or neurologic disease including but not limited to angina pectoris, symptomatic coronary artery disease, uncontrolled hypertension (at time of dosing), NYHA Class III or IV congestive heart failure, confirmed significant cardiac conduction abnormalities (including QTc>0.45 sec) or arrhythmias, myocardial infarction within 12 months, cerebrovascular accidents, or transient ischemic attacks

11) Other conditions which could jeopardize the patientfs ability to comply wiith the protocol including but not limited to dementia, psychosis, or other major psychiatric disorder

12) Known history of hepatitis B, C, or human immunodeficiency (HIV) infection.

.
Links
Registration Number: NCT00658970
Study Information on Clinical Trials Registry (clinicaltrials.gov)

Other Links:
.
Results


Return to Clinical Trials at M.D. Anderson Cancer Center